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Surgical Treatment for Octogenarians with Lung Cancer:
Results from a Population-Based Series of 124 Patients
Hes A. P. Brokx, MD,* Otto Visser, MD, PhD,‡ Pieter E. Postmus, MD, PhD,* and
Marinus A. Paul, MD, PhD†
Introduction: With the increasing life span in the Western world,
the number of octogenarians with resectable, localized non-small
cell lung cancer is increasing. Previous reports on the outcome of
surgery for lung cancer in octogenarians were mainly derived from
single institutions. In contrast, this study presents results for all
hospitals in a region of 3 million inhabitants.
Methods: General data on all patients diagnosed with lung cancer in
the period 1989 to 2004 were retrieved from the Amsterdam Cancer
Registry. Incidence and type of treatment were tabulated and tested for
significance with 2 analysis. Survival was calculated using actuarial
analysis. Absolute and relative survival for octogenarians relative to
other age groups and relative to other treatment modalities in octoge-
narians with clinical stage I/II lung cancer was performed.
Results: Non-small cell lung cancer was diagnosed in 1993 octo-
genarians (14% of all lung cancer patients). One hundred twenty-
four patients (6%) underwent surgery. Five patients died within 30
days of surgery (4%). Relative survival after 1, 2, and 5 years was
83%, 69%, and 47%, respectively. These relative survival figures are
comparable with other age groups. There was a survival benefit for
surgical resection versus radiotherapy and other or no treatment
(relative 5-year survival of 47% versus 3% and 0%, respectively).
Conclusions: Resection rates in octogenarians are low but satisfac-
tory postoperative mortality and acceptable survival suggest that
selection criteria should be adapted. Until effective alternative treat-
ment becomes available, surgical resection, preceded by a thorough
preoperative assessment, should be considered in the “old but fit”
octogenarian.
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Non-small cell lung cancer (NSCLC) represents 80% ofall lung cancers and, like most other cancers, is a disease
of advanced age.1 Because of the longer life span in the
Western world, the number of elderly patients with NSCLC is
increasing. For limited tumors, surgery is the treatment of
choice. Due to advances in anesthesia and postoperative care,
surgery can now be performed in high-risk patients and even
in those of 80 years and older (octogenarians).2,3
Age-related differences in both diagnostic procedures
and treatment have already been reported,4,5 as well as the
limited participation of elderly patients in clinical trials.6,7 A
number of studies report on the use of surgery for elderly
patients with lung cancer, but these are mainly derived from
single, dedicated institutions. Little is known about the treat-
ment and outcome of NSCLC in advanced age groups outside
these specialized centers.
In this report, we present resection rates and survival
outcome for octogenarians with lung cancer who underwent
resection in both general and university hospitals within a
large region.
MATERIALS AND METHODS
Data were retrieved from the Cancer Registry in Am-
sterdam. The current study was performed according to the
Privacy Regulations of the Amsterdam Cancer Registry and
approved by the Amsterdam Cancer Registry Board. The
cancer registry collects information on all cancer diagnoses
and treatment modalities directly from the medical records in
an area with 3 million people (17% of the population in The
Netherlands). The area comprises two university medical
centers, 12 teaching hospitals, and nine district hospitals.
Surgery for lung cancer is performed in 20 of the 23 hospi-
tals. One university medical center and one teaching hospital
have a department of cardiothoracic surgery. In the other
hospitals, including the second university medical center,
general surgeons perform lung cancer surgery.
The median hospital volume is fewer than 20 opera-
tions per year.8 Tumors were classified according to the 1997
TNM classification.
Considerations for surgical resection were in accor-
dance with TNM stage and the patients’ comorbidities, per-
formance status, and consent. However, exact details on
comorbidities and presurgical selection were not separately
collected. For the period 1989 to 2004, we studied the
incidence of NSCLC per age group, the percentage of pa-
tients who underwent surgery, the type of resection, other
treatments, and the survival outcome. We were able to deter-
mine observed and relative survival per age group and per
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treatment modality for the octogenarians group, within the
Amsterdam Cancer Registry region. Relative survival is an
estimation of disease-specific survival. It reflects survival of
cancer patients, adjusted for survival in the general popula-
tion with the same age structure. Relative survival is calcu-
lated as the ratio of the observed to the expected rates.
Expected survival rates were calculated from life tables for
the general population with the same age distribution. Chi-
square analysis was used for proof of significance, and
survival was calculated by actuarial analysis. The life expect-
ancy for an 82-year-old person was estimated using national
life tables.
RESULTS
In the 16-year study period, NSCLC was diagnosed in
14,272 patients, of whom 1993 (14%) were 80 years and
older (Table 1). Resection rates decreased with age from 30%
for patients younger than 70 years to 23% for those aged 70
to 79 and 6% for octogenarians (p  0.01). The group of
octogenarians comprised 107 men and 17 women, with a
mean age of 82 years (median, 82; range, 80–87 years)
(Table 2).
The most frequent operation was a lobectomy (n 87).
Four patients underwent a bilobectomy and 15 patients (12%)
a pneumonectomy. A lesser resection was performed in six
patients, and in the remaining 12 patients, the resection was
not specified. The extent of lymph-node sampling or clear-
ance during surgery was not recorded. Two patients received
neoadjuvant chemotherapy.
Lung surgery was performed in 20 of the 23 hospitals
of the studied region. In two of these 20 hospitals, cardiotho-
racic surgeons performed lung surgery; in the other 18 hos-
pitals, general surgeons performed lung resections. Each of
these 20 hospitals treated elderly patients, with the number of
resections varying from 1 to 16. Neither number nor the
mortality rate per hospital could be obtained for publication,
but mortality rates for lung surgery did not differ significantly
between these hospitals (unpublished data).
The majority of patients had clinical stage I or II
disease. Six patients had clinical stage III disease, while three
patients were classified as stage IV. Eight patients were
up-staged at pathologic examination. (Table 3). Of the clin-
ical stage IV patients, one had two sublobar lesions in two
different lobes, which were resected in one session by two
segmentectomies. The second patient was diagnosed with a
diaphragmatic metastasis, which was resected with the pri- mary lesion. The last patient was diagnosed with a paraesoph-
ageal metastasis, which was also resected with the primary
lesion. Five patients died postoperatively (4%). Of these, one
underwent a right pneumonectomy.
The observed and relative postoperative survival was
74% and 83% after 1 year, 55% and 69% after 2 years, and
24% and 47% after 5 years, respectively, for octogenarians
(Table 4A). The general life expectancy for an 82 year old in
The Netherlands is 5.9 years for men and 7.4 years for
women. Relative 5-year survival rates for the total group of
octogenarians with lung cancer relative to treatment modality
were 47% in the surgical group, 3% in the radiotherapy
group, and 0% in the other/nontreated group, respectively
(Table 4B and Figure 1). Table 4C shows the same survival
TABLE 1. Frequency of NSCLC and Resection Rates by Age
Group, 1989 to 2004
Age (y) No. of Patients % No. %
50 1036 7 354 25
50–59 2162 15 885 29
60–69 4061 28 1738 30
70–79 5020 35 1507 23
80 1993 14 124 6
Total 14,272 100 4608 24
TABLE 2. Age Distribution of Octogenarians Who
Underwent Resection, 1989 to 2004 (n  124)
Age (y) 80 81 82 83 84 85 86 87
No. of patients 37 25 28 21 6 3 2 2
TABLE 3. Patient, Tumor, and Treatment Characteristics of
Surgically Treated Octogenarians, 1989 to 2004
n %
Gender
Male 107 86
Female 17 14
Histology
Squamous cell carcinoma 63 51
Adenocarcinoma 36 29
Adenosquamous carcinoma 6 5
Large cell carcinoma 18 15
Sarcomatoid carcinoma 1 1
Resection type
Left pneumonectomy 12 10
Right pneumonectomy 3 2
Bilobectomy 4 3
Lobectomy 87 70
Sublobar resection 6 5
Not specified 12 10
c Stage (cTNM 1997)
I–II 115 93
III 6 5
IV 3 2
p Stage (pTNM 1997)
IA 30 24
IB 49 40
IIA 3 2
IIB 25 20
IIIA 10 8
IIIB 4 3
IV 3 2
Postoperative mortality
No 119 96
Yes 5 4
Brokx et al. Journal of Thoracic Oncology • Volume 2, Number 11, November 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer1014
rates relative to treatment modality in octogenarians, al-
though corrected for clinical stage I/II lung cancer. The
relative 5-year survival rate for the resection group was 52%;
it was 6% for the radiotherapy group and 2% for the other/no
treatment group.
The most interesting findings for this subset are the
comparable relative survival for surgically treated octogenar-
ians (i.e., 47%) to the younger age groups and the clear
survival benefit of surgical resection in clinical stage I/II
octogenarians as opposed to radiotherapy, no, or other treat-
ment (i.e., 47% versus 6% and 2%, respectively).
DISCUSSION
The number of publications on surgical treatment of
NSCLC in the elderly is increasing, but results are difficult to
compare. Main problem is the absence of a clear definition of
the elderly patient. Geriatric oncology has been operationally
defined as “when the health status of a patient population
begins to interfere with the oncological decision making
guidelines”9 and recommends that decision making is to be
governed by the patient’s performance status rather than by a
fixed age limit.10 However, age limits of 65, 70, 75, or 80
years can still be found in the literature.11–14
The median life expectancy of octogenarians in gen-
eral, 6 years for men and 8 for women, is relatively long
compared with the1.5 years for patients with untreated or
palliated resectable NSCLC. It is clear that the life-limiting
factor in these octogenarians is not their age but rather their
FIGURE 1. Relative survival of octogenarians with lung can-
cer according to treatmentmodality, Amsterdam Cancer
Registry, 1989 to 2004.
TABLE 4. Observed and Relative Survival Analyses of Amsterdam Cancer Registry Data, 1989 to 2004: A, Per Age Group
after Surgical resection; B, for Octogenarians According to Treatment Modality; C, for Clinical Stage I/II Octogenarians
According to Treatment Modality
A. Observed and Relative Survival Rates After Surgical Resection Per Age Group
Age Group No.
Observed Survival Relative Survival
1 yr 2 yr 5 yr 1 yr 2 yr 5 yr
50 354 83 68 53 84 68 54
50–59 885 86 72 52 87 73 54
60–69 1738 81 64 44 82 67 49
70–79 1507 75 59 37 79 66 50
80 124 74 55 24 83 69 47
Total 4608 80 64 43 82 68 51
B. Observed and Relative Survival Rates for Octogenarians According to Treatment Modality
Observed Survival Relative Survival
Treatment No. 1 yr 2 yr 5 yr 1 yr 2 yr 5 yr
Resection 124 74 55 24 83 69 47
Radiotherapy 592 34 14 2 39 18 3
Other/none 1353 15 5 0 17 6 0
Total 2069 24 10 2 27 13 4
C. Observed and Relative Survival Rates for Clinical Stage I/II Octogenarians According to Treatment Modality
Observed Survival Relative Survival
Treatment No. 1 yr 2 yr 5 yr 1 yr 2 yr 5 yr
Resection 115 73 54 26 82 69 52
Radiotherapy 225 47 20 3 54 26 6
Other/none 332 23 8 1 26 11 2
Total 672 40 20 6 45 26 11
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cancer.15 Surgery therefore offers better prospects with re-
spect to length and quality of life than conservative manage-
ment.16 Our data from the Amsterdam Cancer Registry show
the better relative survival of clinical stage I/II octogenarians
treated surgically compared with radiotherapy or no or other
treatment modalities (52% versus 6% and 2%, respectively).
Conventional radiotherapy can be an alternative for patients
with medical contraindications; however, it is associated with
the risk of severe side effects and permanent decrease in lung
function, which is reflected in these survival figures. Unfor-
tunately, as comorbidity has not been scored, it remains
unclear to what extent preexisting comorbidity or treatment
toxicity of radiotherapy contributed to the worse outcome in
these patients.
Fourteen percent of the NSCLC diagnoses in our study
were made in octogenarians. The actual figure may be
slightly higher due to underascertainment and underregistra-
tion. Elderly patients are less likely to be referred to hospital,
and tumors are less often verified by microscopic examina-
tion. Moreover, older patients tend to be less accurately
staged and are often not treated according to protocol.17
With the gradually increasing life expectancy in the
Western world, the number of elderly patients demanding
adequate treatment may increase considerably in the near
future. The low proportion of surgically treated octogenarians
(6%) may be explained by the high prevalence of comorbidity
at this age; unfortunately, comorbidity data were not avail-
able for analysis. In a recent population-based study from a
different area of The Netherlands, the health status of the
patients was also recorded. Nine percent of the octogenarians
underwent surgery, but also in this study, the percentage was
lower than expected according to the comorbidity profile.5
Our study shows that the outcome of surgically treated
octogenarians with NSCLC is satisfying, even in a large
region where patients are mainly treated in general hospitals,
especially if we look at the comparable relative survival of
surgically treated octogenarians relative to the other age
groups in the split sample analysis. Whether the results could
be improved is unknown. Given recent publications on better
outcome in high-volume hospitals,18 discussions on concen-
tration of lung surgery need to be started.
Eighty-five percent of the patients underwent a real
oncologic resection, removal of the primary tumor with the
area of lymph drainage. Only 5% had a sublobar resection.
Lobectomy is still considered the minimal oncologic resec-
tion in NSCLC,19 although recent papers state that smaller
resections should be considered in elderly patients because
the outcome is not severely affected.17,20 In our study, the
proportion of pneumonectomies was high compared with
other studies16,21–23 and comprised 12 resections of the left
lung and three of the right. Right-sided resection carries a
high complication rate and needs to be avoided in elderly
patients.24 A wider application of sleeve-resections might
have reduced the number of pneumonectomies.
Information on postoperative complications was also not
recorded. The postoperative mortality of 4% and the relative
5-year survival rate of 47% are comparable with results reported
for octogenarians in the literature4,11,12,16,21–23,25,26 and are
noteworthy considering the participation of many nonspecial-
ized centers. These relative survival rates for octogenarians
equal those for the other age groups in the studied region.
There are some limitations to our study. First, presurgical
selection and patients comorbidities have not been scored. Sec-
ond, because of its retrospective nature and anonymous regis-
tration, quality-of-life analysis could not be performed.
Despite these limitations, the current study has an
important strength in that it provides insight into the number
of surgical resections for lung cancer in octogenarians being
performed with their accompanying absolute and relative
survival. These numbers clearly show that, although the
selection criteria for surgical resection are not exactly known,
the relative 5-year survival of octogenarians after resection is
comparable with the other age groups. Furthermore, relative
survival rates for surgically treated stage I/II octogenarians
are better than for clinical stage I/II octogenarians receiving
radiotherapy or no therapy.
This study was a population-based study and thus
provides far better insight than most of the previously pub-
lished studies, which were mostly conducted based on spe-
cialized single-center figures.
Thoracic surgery, therefore, seems to be safe and
feasible in this group of selected elderly patients. The
criteria used for selection, although not exactly known,
seem to function well, as long as a comprehensive preop-
erative assessment is performed to select surgical candi-
dates appropriately.
However, several questions remain. First, how many
elderly patients could have received potential curative resec-
tion if less strict criteria were applied and a higher mortality
rate would have been accepted? There is no consensus on the
mortality risk at which surgery is no longer acceptable.
According to Cykert,27 in the absence of other treatment
possibilities, patients tend to accept very high operative risks.
Furthermore, it is said that older patients tend to reject
treatment options if the outcome implies chronic morbidity
and long-term dependency.28
Second, a higher resection rate might be obtained
without increasing the mortality, just by concentration of care
in high-volume hospitals with a comprehensive approach for
treating elderly people.
Third, one should not focus on mortality rates alone
because quality-of-life issues should influence decision mak-
ing as well. For example, in the study of Osaki et al.,12 the
30-day mortality rate was 3%, but 18% of the remaining
patients never left the hospital. Because of this quality-of-life
issue, new treatment options may play an important role in
the future. When elderly patients are offered less aggressive
treatment strategies, they are more inclined to choose these
alternatives.27 Stereotactic limited-field radiotherapy is re-
ported to offer results comparable with those of resection in
localized NSCLC, without the known adverse effects of
conventional radiotherapy.29,30 With modern staging tools
such as positron emission tomography (PET) and ultrasonog-
raphy-guided endoscopy, accurate staging can be performed
and this stereotactic radiotherapy option should be considered
in frail patients.
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CONCLUSION
Fourteen percent of NSCLC occurs in patients 80 years
and older. Only 6% of them underwent resection, with accept-
able postoperative mortality, even in low-volume hospitals.
Relative survival for surgically treated octogenarians was com-
parable with that of other younger age groups, and there was a
relative survival benefit for octogenarians with clinical stage I/II
lung cancer treated surgically relative to octogenarians undergo-
ing radiotherapy or no/other therapy. Until effective alternatives
become available, surgical resection (preceded by meticulous
preoperative assessment) should be and can be offered to the
“old but fit” octogenarian.
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